Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P43489

UPID:
TNR4_HUMAN

ALTERNATIVE NAMES:
ACT35 antigen; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor

ALTERNATIVE UPACC:
P43489; Q13663; Q2M312; Q5T7M0

BACKGROUND:
The protein TNFRSF4, with alternative names such as OX40L receptor and ACT35 antigen, is integral to the immune response, functioning as a receptor for TNFSF4/OX40L/GP34. It is implicated in sustaining long-term T-cell immunity and serves as a receptor for HHV-6B, highlighting its role in microbial infection defense.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of TNFRSF4 could open doors to potential therapeutic strategies for combating Immunodeficiency 16, a disease characterized by a complete functional OX40 deficiency leading to severe immune response impairments. Leveraging TNFRSF4's function offers a promising avenue for novel immunotherapy approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.